1. Home
  2. Shareholder and Investor Information
  3. CJ CheilJedang Co. and RaQualia Pharma Inc. Sign Licensing Agreement for Acid Pump Antagonist

Shareholder and Investor Information

CJ CheilJedang Co. and RaQualia Pharma Inc.
Sign Licensing Agreement for Acid Pump Antagonist

press_20100608

September 6, 2010 - CJ CheilJedang Co. (CJ), CEO: Jinsoo Kim, 5-ga, Namdaemun-ro, Jung-gu, Seoul, 100-749, Korea, and RaQualia Pharma Inc. (RaQualia), CEO: Atsushi Nagahisa, 5-2, Taketoyo, Aichi 470-2341, Japan, today announced the signing of a Licensing Agreement, granting CJ exclusive rights to RaQualia’s Acid Pump Antagonists (RQ-00000004, RQ-00000774).
Under the terms of the agreement, CJ will have Korea and China rights to develop and commercialize RQ-00000004 and RQ-00000774. In return, RaQualia will receive an upfront payment from CJ and is eligible to receive development milestones and royalties on sales of products commercialized under the license.
Both companies signed a Memorandum of Understanding to establish a strategic alliance in the area of innovative gastrointestinal therapies on June 7, 2010.
About Acid Pump Antagonist (RQ-00000004, RQ-00000774)
RQ-00000004 and RQ-00000774 are novel potassium competitive acid pump antagonists (APAs) that inhibit the binding of potassium ion to H+/K+-ATPase. This mechanism of action is fundamentally different from that of proton-pump-inhibitors (PPIs) and it enables more rapid onset of maximum suppression and longer duration of action if an appropriate pharmacokinetic profile is obtained. APAs are expected to improve Gastro-Esophageal Reflux Diseases (GERD) symptom control not adequately addressed by PPI therapy, and have potentials for the treatment of peptic ulcer and other acid-related GI disorders.
 Currently, a Phase 1 study is in progress in the US for RQ-00000004, and a backup compound RQ-00000774 is in pre-clinical development.
Contact
・CJ CheilJedang Co.
Sangman Ahn / Sungbin Cho
Phone: +81-3-3519-3452
Fax: +81-3-3580-1055
E-mail: bean@cj.net
・RaQualia Pharma Inc.
Taisuke Inagaki / Satoko Saito
Phone: +81 569 84 0700
Fax: +81 569 74 1381
E-mail: ask@raqualia.com

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics